Artículos de revistas
Treatment of snoring and sleep apnea syndrome with a removable mandibular advancement device in patients without TMD
Fecha
2012-04-01Registro en:
Dental Press Journal of Orthodontics. Dental Press International, v. 17, n. 2, p. 90-96, 2012.
2176-9451
10.1590/S2176-94512012000200017
S2176-94512012000200017
S2176-94512012000200017.pdf
3000945612440374
0000-0001-5834-105X
Autor
Clinic of Sleep Disorders Sleep Dentistry department of Orofacial Pain
Universidade de São Paulo (USP)
Universidade Estadual Paulista (Unesp)
Clinic of Sleep Disorders
UNIFLU FOC Head of Dental Prosthesis
Paraná Federal University Department of Dental Prosthesis
Institución
Resumen
INTRODUCTION: Among the sleep disorders reported by the American Academy of Sleep, the most common is obstructive sleep apnea-hypopnea syndrome (OSAHS), which is caused by difficulties in air passage and complete interruption of air flow in the airway. This syndrome is associated with increased morbidity and mortality in apneic individuals. OBJECTIVE: It was the objective of this paper to evaluate a removable mandibular advancement device as it provides a noninvasive, straightforward treatment readily accepted by patients. METHODS: In this study, 15 patients without temporomandibular disorders (TMD) and with excessive daytime sleepiness or snoring were evaluated. Data were collected by means of: Polysomnography before and after placement of an intraoral appliance, analysis of TMD signs and symptoms using a patient history questionnaire, muscle and TMJ palpation. RESULTS: After treatment, the statistical analysis (t-test, and the before and after test) showed a mean reduction of 77.6% (p=0.001) in the apnea-hypopnea index, an increase in lowest oxyhemoglobin saturation (p=0.05), decrease in desaturation (p=0.05), decrease in micro-awakenings or EEG arousals (p=0.05) and highly significant improvement in daytime sleepiness (p=0.005), measured by the Epworth Sleepiness Scale. No TMD appeared during the monitoring period. CONCLUSION: The oral device developed in this study was considered effective for mild to moderate OSAHS.